Si-Jia Zhu

Dr. Si-Jia Zhu


Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2022 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
MYMing Yang
Ming Yang
CSChen Shen
Chen Shen
SZSi-Jia Zhu
Si-Jia Zhu
YZYao Zhang
Yao Zhang
HJHong-Lin Jiang
Hong-Lin Jiang
JLJian-Ping Liu
Jian-Ping Liu

10 November 2021 in Integrative Medicine Research
Verified
Journal Article
Open access
SZSi-Jia Zhu
Si-Jia Zhu
RWRui-Ting Wang
Rui-Ting Wang
ZYZe-Yu Yu
Ze-Yu Yu
RZRuo-Xiang Zheng
Ruo-Xiang Zheng
CLChang-Hao Liang
Chang-Hao Liang
JLJian-Ping Liu
Jian-Ping Liu
Myasthenia Gravis (MG) is a disorder of neuromuscular transmission bringing mild ocular weakness to severe generalized muscle weakness and disability. The conventional treatments have long-term side effects, and Chinese herbal medicines (CHM) have shown possible effect and safety for MG patients, but the existing evidence was not robust enough and the results were out of date. Searching for randomized controlled trials (RCTs) was conducted in 7 databases and clinical trial registries until July 2021. The ROB 2 tool was used to assess the study quality and GRADE was used to assess the quality of whole evidence. Meta-analyses were conducted and the results were presented as risk ratio (RR) or mean difference (MD) with 95% confidence interval (CI). Nineteen RCTs (1283 participants) testing 13 kinds of CHM with adequate randomization were included and six RCTs investigating Compound Huangqi were included in the meta-analyses. In addition to conventional treatment, nine CHMs reduced symptom scores of MG. Compound Huangqi plus conventional treatment (pyridostigmine bromide or prednisone or both) reduced the symptom scores compared with conventional treatment (MD = -3.56, 95%CI -4.86 to -2.26). Less adverse events happened in the CHM groups (3/247 in the CHM groups, 52/245 in the control groups, RR = 0.13, 95%CI 0.06 to 0.30, 9 RCTs, a total of 492 participants). The effect on quality of life was inconsistent. Nine CHMs could probably bring benefit for MG symptom improvement. Moderate to low certainty of evidence supported Compound Huangqi added-on conventional treatment probably bring extra benefit of improving MG symptoms. Adding CHMs could be safer than giving only conventional treatment. The protocol was registered in PROSPERO (ID: 32718).

15 August 2019 in Systematic Reviews
Verified
Journal Article
Open access
PDF file
RMRuan Nilton Rodrigues Melo
Ruan Nilton Rodrigues Melo
SFStephanie Carolina Francisco
Stephanie Carolina Francisco
CMCaroline de Castro Moura
Caroline de Castro Moura
KLKirsty Loudon
Kirsty Loudon
NSNamie Okino Sawada
Namie Okino Sawada
Ana Cláudia Mesquita GarciaAna Cláudia Mesquita Garcia
Ana Cláudia Mesquita Garcia
Due to the worldwide rise in cancer incidence, and therefore the rise in the need for antineoplastic chemotherapy, it is important for both healthcare professionals and patients alike that the side effects of chemotherapy, such as chemotherapy-induced nausea and vomiting (CINV), are treated and prevented. Auriculotherapy is a type of acupuncture and may be a low-cost and safe antiemetic measure to control the side effects of chemotherapy. The goal of this systematic review is to synthesize the available evidence in the literature regarding the auriculotherapy effects to treat CINV in people with cancer. The review will only include randomized controlled trials (RCTs) that compare the clinical effects of the auriculotherapy intervention (used alone or as an add-on), with sham auriculotherapy, routine treatment with antiemetic drugs, or other non-pharmacological interventions in patients with cancer with CINV who are undergoing chemotherapy. The outcomes to be evaluated are nausea and vomiting: in acute, delayed, or anticipated stages, when induced by chemotherapy. A comprehensive search for studies will be carried out in these databases: MEDLINE via PubMed, EMBASE, CINAHL, Cochrane Central Register of Controlled Trials, ICTRP, LILACS, CUMED, IBECS, BVS MTCI Americas, Web of Science, Scopus, PEDro, CNKI, and CBMdisc up until December 31, 2018. Only articles in English, Portuguese, and Spanish will be selected. Two independent reviewers will evaluate full texts, extract data, and assess the risk of bias of eligible articles. The quality of evidence will be assessed using Grading of Recommendations, Assessment, Development and Evaluation (GRADE). A meta-analysis will be undertaken to assess the interventions and outcomes’ homogeneity, assessing statistical heterogeneity using the Cochran’s Q test and quantified using Higgins’ inconsistency index. If there is insufficient data for a meta-analysis, a narrative synthesis will be presented. This protocol has been prepared according to the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines. The results of this systematic review will summarize the strength of evidence for the use of auriculotherapy in the control of CINV of patients with cancer and will be used to identify evidence gaps. PROSPERO CRD42018117513

11 March 2023 in Journal of Traditional Chinese Medical Sciences
Verified
Journal Article
Open access
JLJianping Liu
Jianping Liu
SZSi-Jia Zhu
Si-Jia Zhu
NRNicola Robinson
Nicola Robinson

31 December 2018 in Journal of Traditional Chinese Medical Sciences
Verified
Journal Article
Open access
PDF file
CLChunli Lu
Chunli Lu
XJXinyan Jin
Xinyan Jin
DWDarong Wu
Darong Wu
SZSi-Jia Zhu
Si-Jia Zhu
LLLily Lai
Lily Lai
JLJianping Liu
Jianping Liu
Objective: Due to a lack of available effective treatments for atopic eczema (AE), non-pharmaceutical therapy such as Tuina has been frequently sought after as an alternative treatment. We evaluated the benefits and harms of Tuina for children with AE under 14 years of age. Methods: We searched for randomized controlled trials (RCTs) on Tuina in seven Chinese and English databases from their inception to June 2018. We included children under 14 years of age with AE received Tuina alone or combined with conventional medicine. Two authors independently extracted data and used the Cochrane "Risk of bias" tool to assess the methodological quality. Effects were presented as relative risk with 95% confidence interval using RevMan 5.3. Data not suitable for statistical pooling were synthesized qualitatively. Results: Nine RCTs involving 1 246 children with AE were included. The trials were at unclear or high risk of bias. Tuina manipulation in each trial was different. Compared to usual care, three trials showed greater effects of Tuina alone or combined with usual care for global symptoms and signs improvement, such as itching, and skin lesions. Four trials showed that Tuina had ≥50% improvement in symptoms and signs. Due to clinical heterogeneity, meta-analysis was not possible. At follow-up of between 4 weeks and 6 months, five trials of Tuina alone or Tuina combined with usual care showed lower rates of relapse compared to usual care alone. Four trials reported no occurrence of severe adverse events. Conclusions: Limited evidence demonstrates that Tuina may improve symptoms and signs of AE and reduce relapse rate in children <14 yrs with AE. Tuina is generally acceptable in these trials. Further well-designed RCTs are warranted to confirm these benefits and to explore safety further.